Magnification requirement after photodynamic therapy with verteporfin for subfoveal predominantly classic choroidal neovascularization due to age-related macular degeneration

European Journal of Ophthalmology

Volumn 15, Issue 6, 2005, Pages 768-773

  Thoelen, A M ^a   Bernasconi, P P ^b   Buser, F ^c   Fierz, A B ^a   Messmer, E P ^a  

^a TRIEMLI HOSPITAL   (Switzerland)

^b Augenklinik Spital Oberengadin   (Switzerland)

^c Fachstelle Low Vision Entwicklung SZB   (Switzerland)

Author keywords

Age related macular degeneration; Magnification requirement; Near vision; Photodynamic therapy; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ARTICLE; CONTRAST SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; READING; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 30444440913     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210501500618     Document Type: Article

References (25)

1. Ciulla TA, Danis RP, Harris. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 1998; 43: 134-46.
2. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 2000; 84: 244-50.
3. Thall EH, Miller KM, Rosenthal P, Schechter RJ, Steinert RF. Approach to the patient with low vision. In: The Foundation of the American Academy of Ophthalmology. Basic and Clinical Science Course, Volume 3. San Francisco: American Academy of Ophthalmology; 2001.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neo-vascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999; 117: 1329-45.
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neo-vascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report no. 2. Arch Ophthalmol 2001; 119: 198-207.
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity-TAP report no. 4. Retina 2002; 22: 536-44.
7. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP report no. 5. Arch Ophthalmol 2002; 120: 1307-14.
8. Buser F. Der SZB-Test zum Messen des Vergrösserungsbedarfes. Schweizer Optiker 1992; 3: 4-6.
9. Verteporfin Roundtable Participants, TAP Study Group, VIP Study Group. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002; 22: 6-18.
10. Thölen AM, Bernasconi PP, Fierz A, Messmer EP. Lesefähigkeit nach photodynamischer Therapie für altersabhängige Makuladegeneration (AMD) und für hohe Myopie. Ophthalmologe 2003; 100: 28-32.
11. Sloan L, Brown DJ. Reading carts for selection of optical aids for the partially sighted. Am J Ophthalmol 1963; 55: 1187.
12. Faye EE. Low vision. In: Tasman W, Jaeger EA, eds. Duane's Clinical Ophthalmology, Vol 1. Philadelphia: J.B. Lippincott Company; 1993: 1-14.
13. Axer-Siegel R, Ehrlich R, Yassur Y, et al. Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns. Am J Ophthalmol 2004; 137: 258-64.
14. Rohrschneider K. Nutzung und Akzeptanz von vergrössernden Sehhilfen. Klin Monatsbl Augenheilkd 2002; 219: 507-11.
15. Stelmack J. Reading performance of geriatric patients post exudative maculopathy. J Am Optom Assoc 1991; 62: 53-7.
16. Virtanen P, Laatikainen L. Low-vision aids in age-related macular degeneration. Curr Opin Ophthalmol 1993; 3: 33-5.
17. Ducrey N. Suivi des patients atteints de dégéné rescence maculaire liée à l'age équipés d'aides visuelles. Klin Monatsbl Augenheilkd 2000; 216: 278-82.
18. Grein H.-J. Low Vision-Versorgung Sehbehinderter mit vergrössernden Sehhilfen. Teil II: Anpassung und Verordnung. Ophthalmologe 2002; 99: 884-98.
19. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108: 2051-9.
20. Macular Photocoagulation Study Group. Visual outcome after laser photo-coagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994; 112: 480-8.
21. Radner W, Willinger U, Obermayer W, Mudrich C, Velikay-Parel M, Eisenwort B. Eine neue Lesetafel zur Bestimmung von Lesevisus und Lesegeschwindigkeit. Klin Monatsbl Augenheilkd 1998; 213: 174-81.
22. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220-31.
23. Ergun E, Maar, Radner W, et al. Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 2003; 110: 65-9.
24. Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G, Michels SM. Effects of verteporfin therapy on central visual field function. Ophthalmology 2004; 111: 931-9.
25. Watson GR. National survey of the impact of low vision device use among veterans. Optom Vis Sci 1997; 74: 249-59.